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Abstract
A solid process for diagnosis could have a substantial impact on the successful treatment of pancreatic cancer, for which
currently mortality is nearly identical to incidence. Variations in the abundance of all microRNA molecules from peripheral
blood cells and pancreas tissues were analyzed on microarrays and in part validated by real-time PCR assays. In total, 245
samples from two clinical centers were studied that were obtained from patients with pancreatic ductal adenocarcinoma or
chronic pancreatitis and from healthy donors. Utilizing the minimally invasive blood test, receiver operating characteristic
(ROC) curves and the corresponding area under the curve (AUC) analysis demonstrated very high sensitivity and specificity
of a distinction between healthy people and patients with either cancer or chronic pancreatitis; respective AUC values of
0.973 and 0.950 were obtained. Confirmative and partly even more discriminative diagnosis could be performed on tissue
samples with AUC values of 1.0 and 0.937, respectively. In addition, discrimination between cancer and chronic pancreatitis
was achieved (AUC=0.875). Also, several miRNAs were identified that exhibited abundance variations in both tissue and
blood samples. The results could have an immediate diagnostic value for the evaluation of tumor reoccurrence in patients,
who have undergone curative surgical resection, and for people with a familial risk of pancreatic cancer.
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Introduction
Pancreatic cancer is one of the most aggressive and malignant
tumor entities with a five-yearsurvival rate oflessthan 5%[1].Most
patients die within a year of diagnosis. The poor prognosis is caused
by the lack of both appropriate markers for early diagnosis and
effective treatment options for the late stages that are consequently
seen in clinics. Since mortality is nearly identical with incidence,
pancreatic cancer is the fourth to fifth most common cause of
cancer-related deaths in industrialized countries. Extensive studies
have been performed in order to identify biomarkers for the disease.
Some have been or are currently being evaluated, such as
CEACAM-1, MIC-1, PAM4 and CA19-9; the last is the only
blood-borne biomarker in routine clinical use for management of
pancreatic cancer. At the level of messenger RNA (mRNA), quite a
few, including some very specific molecular variations have been
found in tissues [2]. However, none of these markers has proven
helpful in facilitating diagnosis [3], largely due to the real difficulty
in obtaining biopsy material and the dilemma that the performance
of biopsies is inappropriate without prior indication of disease.
More recently, microRNAs (miRNAs) have gained attention as
possible biomarkers. They belong to the group of small non-coding
RNAs and have essential functions in various biological processes
[4]. In addition, the molecules are stable in comparison to mRNA,
which is of considerable importance for the robustness of
diagnostic assays. About 1000 miRNAs are believed to occur in
humans and are considered to form a distinct layer of regulation of
cellular function. Several miRNAs were found to be associated
with tumor-relevant processes [5]. Similar to mRNA profiling,
miRNA signatures exhibited distinctive expression variations in
pancreatic tumor samples, chronic pancreatitis tissue and normal
pancreas [6,7]. Expression abnormalities in pancreatic endocrine
and acinar tumors were associated with distinctive pathologic
features and clinical behavior [8]. Also, a relationship of the
expression of particular miRNA and survival of patients with
pancreatic adenocarcinoma was reported [9]. The transcripts
miR-21, miR-155, miR-203, miR-210 and miR-222 were
described as potential predictors of survival [10,11]. However,
the tissue-based miRNA studies also suffer from the fact that
invasive action is required to acquire material for analysis, and as
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progress compared to messenger RNA profiling but for the
superior stability of miRNA.
Markers that occur in peripheral blood or other body fluids
would be best for detection. For various tumor entities,
extracellular nucleic acids have been found in serum, for example
[12]. In part, they have their origin in circulating tumor cells.
Moreover, the actual tumor cells themselves could be isolated from
blood and used as a means for diagnosis and prognosis [13].
Recently, accumulating data have become available which
indicate that a diagnosis of different forms of disease, including
cancers, may be possible by analyzing the miRNA levels in serum
(e.g., [14,15]). For pancreatic cancer, an analysis of the variations
in plasma of four miRNAs has been reported [16]. In a slightly
different approach, we studied variations of the miRNA levels in
blood cells. In a multicenter study [17], combining 454 samples,
we were recently able to discriminate between 13 disease
conditions and healthy control individuals. In extension to this,
we analyzed here the actual power of miRNA signatures in blood
cells for diagnosis and compared them to signatures obtained from
pancreatic tissue samples. Both the blood and tissue samples were
taken from patients with pancreatic ductal adenocarcinoma,
chronic pancreatitis or from healthy individuals. From the results,
highly accurate molecular classifiers could be defined. In addition,
the variations observed in blood and tissue were compared in
order to detect possible functional connections between them. The
blood analysis permitted distinction of healthy and diseased
pancreas but did not yield sufficient information to separate
pancreatic inflammation from cancer. The tissue analysis,
however, showed differences between inflammation and tumor.
In combination, this process may enable a differential and initially
minimally invasive identification of disease, in particular for the
evaluation of tumor reoccurrence in patients, who have undergone
curative surgical resection, and for people with a familial risk of
pancreatic cancer.
Results
miRNA profiles
In total, the complete miRNA signatures of 245 samples were
analyzed. Relevant sample information is shown in Tab. S1. The
129 tissue samples consisted of 94 samples of pancreatic ductal
adenocarcinoma, 19 samples of chronic pancreatitis and 16
normal tissues. All donors of normal tissue had died from
complications other than pancreatic disease. Histology was done
on all tissue samples in order to use only material of good and
matching quality. The 116 blood samples were collected from a
separate group of people: 45 samples were from patients with
pancreatic ductal adenocarcinoma, 38 from chronic pancreatitis
patients and 33 from healthy individuals. MicroRNA abundance
was analyzed using the Geniom Real Time Analyzer and the
Geniom biochip miRNA homo sapiens. Since the miRBase
database, from which the sequences were taken, was upgraded
twice from version 12.0 to 14.0 during the course of this work, the
863 miRNAs that were consistently present in all three versions
were used for the final data analysis. Overall, 159 and 215
miRNAs exhibited significant expression variations in either blood
or tissue, respectively (see Tab. S2); typical results are shown in
Fig. 1. For independent confirmation, 398 real-time PCR assays
were performed in triplicate. Taking into account the well-
Figure 1. Barplots detailing intensity values recorded for particular miRNAs that exhibited significant expression variations. Only
one typical result each is shown for blood and tissue. In the two panels on the left, the intensity values of miR-320a in blood samples are presented.
The two panels to the right show the values of miRNA-103 as recorded in tissue samples. The horizontal lines in each panel represent the respective
median.
doi:10.1371/journal.pone.0034151.g001
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particular for individual RNA-molecules, the results were in
overall agreement with the information obtained from the
microarray analyses (see Tab. S3). The significantly informative
miRNAs were unevenly distributed between the pair-wise
comparisons. In blood, 87 and 18 miRNAs differentiated between
patients with ductal adenocarcinoma or chronic pancreatitis,
respectively, and healthy individuals. Another 54 miRNAs were
significantly different in both cancer and chronic pancreatitis
compared to normal samples. However, there was not a single
miRNA in blood that permitted drawing a distinction between the
two diseases (Fig. 2; Tab. S2). Conversely, there were 100 miRNAs
found in the tissue samples that permitted a separation of patients
with ductal adenocarcinoma from those with chronic pancreatitis.
In opposition to this, a mere six miRNAs (miR-7, miR-151-3p,
miR-194, miR-486-5p, miR-514 and miR-1206) were discrimi-
native only between chronic pancreatitis and normal tissue,
substantially fewer than in the blood assay. Another 29 miRNAs
were shared by cancer and pancreatitis as less specific markers for
a disease of the pancreas (Tab. S2).
Definition of classifiers
No particular miRNA, however, was informative enough for a
diagnosis of an individual patient because of the individual degree
of variation, as apparent from the barplot results in Fig. 1 for
example, although some are highly relevant population-wide or for
a larger cohort such as the overall group of people examined in
this study. Mutual Information (MI) [18] is a good measure to
estimate the diagnostic information content of single biomarkers.
However, even the miRNAs with the highest MI values were not
sufficiently able to differentiate between healthy and diseased
individuals with high specificity. For example, miR-320a (Fig. 1)
separates blood cells of tumor patients from blood cells of healthy
individuals with a specificity of 73% only, although exhibiting a
high MI of 0.37 and an adjusted p-value of 0.002. In order to
improve assay reliability and robustness, the predictive power of
multiple miRNAs was combined by using statistical learning
techniques. Support Vector Machines (SVM) were applied and a
hypothesis test based on subset selection was carried out. For
statistical significance, 100 repetitions of standard 10-fold cross
validation were done. Likewise, 100 repetitions were computed for
control permutation tests, in which samples with randomly
assigned class labels were classified. The classification values
obtained for accuracy, specificity and sensitivity are shown in Fig.
S1 and visualized as receiver operating characteristics (ROC)
curves in Fig. 3. In blood, area under the curve (AUC) values of
0.973 and 0.950 demonstrate the very high sensitivity and
specificity of discriminating between healthy people and patients
with cancer or chronic pancreatitis, respectively. The blood-based
discrimination of cancer and pancreatitis proved no better than
chance as indicated by the low AUC value and the similar results
of the permutation tests (Fig. S1). For the other comparisons,
however, significant figures were obtained, while the control
permutation tests produced values that correspond to chance, as
expected. This demonstrates that the real figures are not due to an
over-fitting of the statistical model. Confirmative and in part even
better diagnosis could be achieved with tissue samples. The AUC
values for discriminating between healthy people and patients with
cancer or chronic pancreatitis are 1.0 and 0.937, respectively. In
addition, discrimination between cancer and chronic pancreatitis
was achieved (AUC=0.875). The results are consistent with the
findings of unsupervised cluster analyses, also confirming the
suitability of miRNA signatures for diagnostic purposes (not
shown). The molecules producing the best classification results are
labeled in Tab. S2. Dependent on the specific comparison,
variable numbers were required. In tissue, only five molecules
were sufficient for discrimination between cancer and normal,
while 36 molecules were found necessary for the blood-based
analysis.
The specificity of the identified miRNA marker molecules is
documented in a Venn diagram (Fig. 4). To check whether any
overlap of miRNA variations that are part of all three sets is
statistically significant, 100,000 permutation tests were performed.
The only very significant overlap for a pair-wise comparison was
detected for miRNAs in tissue that were significant in both the
cancer versus normal and cancer versus chronic pancreatitis
comparisons. Here, we found 33 overlapping miRNAs while by
chance only 17 would be expected (p=0.00002). Likewise very
significant was the overlap between all three sets. Here, the
analysis predicted an average overlap of 3 miRNAs by chance
while we computed an overlap of 10 miRNAs (p=0.0006). The
relevant miRNA molecules are listed in Fig. 4.
Discussion
The measurement of miRNAs in blood offers an option for the
non-invasive detection of chronic pancreatitis or pancreatic
cancer. The accuracy of discrimination from any other disease is
at least 81.3% [17], even if there is no prior knowledge about the
disease status. Even without a therapeutic advance, this result is
Figure 2. Number of significantly informative miRNAs in blood. The distribution of the 863 miRNAs across the entire p-value range is shown.
The blue line denotes a significance value of 0.05. The bar to the left therefore indicates the number of significantly differentially expressed miRNAs.
For classification purposes, however, also molecules of less significance could be informative.
doi:10.1371/journal.pone.0034151.g002
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curative resections. Also, for the evaluation of tumor reoccurrence
in patients, who have undergone curative surgical resection, and
for people with a familial risk of pancreatic cancer, the miRNA
analysis could have a substantial effect on survival. The miRNA
assay combines a minimally invasive nature with a robustness of
the analyte molecules. The miRNA signatures exhibited enough
reproducibility between patients for a robust detection of disease.
The number of marker molecules required for such a result is
nevertheless small enough to fit to assay systems used in routine
diagnostics, in particular real-time PCR [19]. Both the blood and
the tissue profiling could be supplemented by other data, such as
messenger RNA profiles on tissue biopsy samples [20] or the
resected tumor, produced from the very RNA-preparations utilized
for miRNA detection. Also the testing of other body fluids and the
combination with other analyte forms should improve the solidity
and accuracy of non-invasive testing even further. For example,
particular protein signatures in urine were recently reported [21,22]
that were indicative for pancreatic ductal carcinoma.
The analysis presented here was aimed at the establishment of a
diagnostic modality. The apparent overlap of differentially
expressed miRNAs in blood cells and tissues (Fig. 4) may indicate
a functional relationship. Functional aspects of the miRNA level
variations or groups thereof need to be studied further in order to
elucidate the reason why clear variations can be found in both
blood and tissue of diseased people and if the changes have a
functional connection. In tissue, we also studied the mRNA level
variations in the same set of RNA preparations. A comparative
analysis of the miRNA and mRNA profiles is ongoing and will
provide additional information on the functional effects of changes
of miRNA expression in tumors and inflamed pancreas.
The hypothesis exists that inflammation, such as chronic
pancreatitis, could be required as one step toward the develop-
ment of pancreatic cancer. Given the fact that not all cases of
pancreatic cancer are associated with chronic pancreatitis, it could
be that other forms of inflammation have a similar effect. Although
the actual inflammation may have occurred earlier and even gone
unnoticed phenotypically, it may be possible that a miRNA
signature, which is similar to the one observed for chronic
pancreatitis, could serve as an indicator for an increased risk of
developing pancreatic cancer, while the profiles of other
inflammation diseases, such as the ones of chronic sarcoidosis,
periodontitis and chronic obstructive pulmonary disease, which
are clearly different [17], do not implicate a risk. Further studies
are required to substantiate this assumption.
Materials and Methods
Ethics statement
For all samples analyzed, written informed consent was
obtained from the patients and healthy individuals. Ethical
approval was obtained from local ethics committees at the
universities of Liverpool and Heidelberg; positive ethics votes
301/2001 (tissue) and 159/2002 (blood) of 28 December 2007.
Figure 3. ROC curves calculated on the basis of the miRNA measurements. Receiver operating characteristic (ROC) curves are a widely
accepted indicator of diagnostic utility. Measure of accuracy is the corresponding area under the ROC curve, denoted as AUC. It ranges in value from
0.5 (chance) to 1.0 (perfect discrimination).
doi:10.1371/journal.pone.0034151.g003
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Allpatients included inthis study were of stagesII,III and IV and
were untreated at the time of sample collection. The pancreatic
tissue specimens were collected during surgery. The samples were
snap-frozen in liquid nitrogen directly after resection and
subsequently stored at 280uC until used for RNA preparation.
For RNA isolation from blood, 5 ml blood were collected in
PAXgene Blood RNA tubes (BD, Franklin Lakes, USA). No cancer
treatment had been administered prior to sample collection.
RNA isolation
Patient blood samples were centrifuged at 5000 g for 10 min at
room temperature. For the isolation of total RNA including
miRNA from the cell pellet, the miRNeasy kit (Qiagen, Hilden,
Germany) was used according to the manufacturer’s instructions.
The resulting RNA was stored at 280uC.
Tissue samples were cut into slices of 20 mm thickness with a
cryotome Leica CM 1850 UV at 234uC. During the process, also
thinner slices were produced and studied histologically to assure
that similar tissue qualities were used; the images can be made
available. The 20 mm slices were submerged in liquid nitrogen and
gently ground by three turns with a polypropylene micropestle
(Eppendorf, Hamburg, Germany) that fits into 2 ml Eppendorf
tubes. Total RNA was isolated with the AllPrep Isolation kit
(Qiagen, Hilden, Germany), following a slightly modified protocol.
Eighty percent ethanol was used for washing in order to obtain the
small miRNA molecules. RNA integrity was evaluated using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, USA).
Biochip hybridization and data processing
Samples were analyzed with the Geniom Realtime Analyzer
(febit biomed, Heidelberg, Germany) using the Geniom Biochip
miRNA homo sapiens. Each array contained seven replicates of all
miRNAs as annotated in the Sanger miRBase [23]. Since the
miRBase was upgraded twice from version 12.0 to 14.0 during the
course of this work, the 863 miRNAs that were consistently
present in all three versions were used for the final data analysis.
Hybridization was at 42uC for 16 h in 2.5 M TMAC, 16MES,
20 mM EDTA, pH 8, 0.01% Tween-20, 0.1 mg/ml herring sperm
DNA and 33 ng/ml of directly labeled control oligonucleotides.
Sample labeling with biotin was carried out by a microfluidic-
based enzymatic on-chip protocol [24] and Flash-Tag RNA
labeling (Genisphere, Hatfield, USA) according to manufacturer’s
protocol. Subsequently, the biochip was washed automatically and
a program for signal enhancement was processed using a
streptavidin-phycoerythrin conjugate (Invitrogen, Karlsruhe, Ger-
many) and biotinylated anti-streptavidin goat antibody (Vector
Laboratories, Peterborough, UK). The resulting images of the
signal intensities were evaluated using the Geniom Wizard
Software. Following background correction, the median was
calculated from the seven replicate intensity values of each
miRNA. For data normalization, variance stabilizing normaliza-
tion (VSN) [25] was applied. Checking the technical reproduc-
ibility between experiments exhibited a mean correlation factor of
0.97. The microarray data were deposited in the publicly
accessible database Gene Expression Omnibus (GEO; http://
www.ncbi.nlm. nih.gov/projects/geo/, GSE24279). Also, the
information is attached as Tab. S4.
Evaluation by real-time PCR
Each RNA sample was checked for genomic DNA contamina-
tions that could obscure the measurement. Total RNA was
converted to cDNA using the miScript Reverse Transcriptase mix
(Qiagen, Hilden, Germany) following the manufacturer’s instruc-
tions. Quantification by real-time PCR was performed on a Light
Figure 4. Venn diagram of the overlap of miRNA biomarkers. The miRNAs that are significant and specific for a blood-based diagnosis in
patients with cancer versus healthy donors are shown in the yellow circle. The blue circle represents the markers that discriminate cancer and normal
tissue, while the green circle stands for the markers that permit a distinction of cancer and inflammation in tissue, which is not possible in blood. The
overlap in miRNAs between the tissue marker sets is significant; the relevant molecules are named.
doi:10.1371/journal.pone.0034151.g004
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using the miRNA SYBR Green PCR Kit and the QuantiTect
primer assays (Qiagen). In tissue, 8 miRNAs were analyzed in 9
normal and 22 cancer samples. In blood, 5 miRNAs were
confirmed in 10 samples each of ductal adenocarcinoma, chronic
pancreatitis and healthy. Each analysis was done in triplicate,
totaling 1194 reactions (Tab. S3).
Statistical analysis
All statistical analyses were performed using R (http://www.R-
project.org). Hierarchical clustering analysis was performed with
the hclust function and Heatplus package. For top-down complete
linkage clustering the Euclidian distance was used. The resulting
dendrograms were cut at different heights and Fisher’s exact test
[26] (unpaired, two-tailed) was applied to compute p-values. To
detect miRNAs that showed significant expression variations, we
applied hypothesis testing for pair-wise comparisons. Following
verification of an approximately normal distribution using a
Shapiro-Wilk test [27], non-parametric Wilcoxon-Mann-Whith-
ney tests [28] (unpaired, two-tailed) were computed for each
miRNA. The resulting p-values were adjusted for multiple testing
by Benjamini-Hochberg adjustment [29,30].
Classification of samples using miRNA patterns was carried out
using Support Vector Machines (SMV) as implemented in the R
e1071 package [31] together with a miRNA subset selection
technique. The most common SVM kernels, including linear
SVMs, radial basis function, sigmoid kernels, as well as quadratic
and polynomials were applied. The results presented in this study
rely on the radial basis function SVM, showing superior
performance compared to other kernels. The measured miRNA
profiles were classified using 100 independent repetitions of 10-fold
cross-validation. As a result, the mean accuracy, specificity, and
sensitivity were calculated together with the 95% confidence
intervals. To check for a so-called overtraining, we applied non-
parametric permutation tests. For this, the class labels were
sampled randomly and classifications were carried out using the
permuted class labels. For computing the ROC curves, we used
the bioconductor R package ‘‘ROC’’.
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